Defining conversion therapy for esophageal squamous cell carcinoma

Satoru Matsuda; Takahiro Tsushima; Ken Kato; Chih Hung Hsu; Jang Ming Lee; Ian Yu Hong Wong; Hu Lin Christina Wang; Chang Hyun Kang; Xufeng Guo; Shun Yamamoto; Takayuki Tsuji; Hirofumi Kawakubo; Hiroya Takeuchi; Simon Law; Yuko Kitagawa

doi:10.1002/ags3.12623

Defining conversion therapy for esophageal squamous cell carcinoma

Satoru Matsuda, Takahiro Tsushima, Ken Kato, Chih Hung Hsu, Jang Ming Lee, Ian Yu Hong Wong, Hu Lin Christina Wang, Chang Hyun Kang, Xufeng Guo, Shun Yamamoto, Takayuki Tsuji, Hirofumi Kawakubo, Hiroya Takeuchi, Simon Law, Yuko Kitagawa

研究成果: Editorial › 査読

本文言語	English
ページ（範囲）	7-9
ページ数	3
ジャーナル	Annals of Gastroenterological Surgery
巻	7
号	1
DOI	https://doi.org/10.1002/ags3.12623
出版ステータス	Published - 2023 1月

ASJC Scopus subject areas

外科
消化器病学

文献へのアクセス

10.1002/ags3.12623

他のファイルとリンク

引用スタイル

@article{d39fba93c28e49b1bfc03dc87aca1854,

title = "Defining conversion therapy for esophageal squamous cell carcinoma",

keywords = "conversion surgery, conversion therapy, esophageal squamous cell carcinoma",

author = "Satoru Matsuda and Takahiro Tsushima and Ken Kato and Hsu, {Chih Hung} and Lee, {Jang Ming} and Wong, {Ian Yu Hong} and Wang, {Hu Lin Christina} and Kang, {Chang Hyun} and Xufeng Guo and Shun Yamamoto and Takayuki Tsuji and Hirofumi Kawakubo and Hiroya Takeuchi and Simon Law and Yuko Kitagawa",

note = "Funding Information: Conflict of Interest: Yuko Kitagawa reports grants and personal fees from Asahi Kasei Pharma Co., grants, personal fees, and other from Ono Pharmaceutical Co., Ltd., grants and personal fees from Otsuka Pharmaceutical Factory, Inc., grants and personal fees from Nippon Covidien Inc., grants, personal fees, and other from Taiho Pharmaceutical Co., Ltd, grants, personal fees, and other from Chugai Pharmaceutical Co., Ltd., grants, and personal fees from Kaken Pharmaceutical Co., Ltd., personal fees from AstraZeneca K.K., personal fees from Ethicon, Inc., personal fees from Olympus Co., personal fees from Shionogi & Co., Ltd., personal fees and other from Bristol‐Myers Squibb K.K., personal fees from MSD K.K., personal fees from Smith & Nephew KK, personal fees from Aska Pharmaceutical Co., Ltd., personal fees from Miyarisan Pharmaceutical Co. Ltd., personal fees from Toray Industries, Inc., personal fees from Daiichi Sankyo Company, Ltd., personal fees from Chugai Foundation for Innovative Drug Discovery Science, personal fees from Nippon Kayaku Co., Ltd., grants from Yakult Honsha Co. Ltd., grants from Otsuka Pharmaceutical Co., Ltd., grants from Tsumura & Co., grants from Sumitomo Pharma Co., Ltd., grants from EA Pharma Co., Ltd., grants from Eisai Co., Ltd., grants from Kyowa Kirin Co., Ltd., grants from Medicon Inc., grants from Takeda Pharmaceutical Co., Ltd., grants from Teijin Pharma Ltd., outside the submitted work; Ken Kato reports research grants from MSD; Ono Pharmaceutical Co.; Merck Serono; Bayer; Beigene; Oncologys Biopharma; Chugai Pharmaceutical Co.; and Shionogi. Satoru Matsuda, Hiroya Takeuchi, Simon Law, and Yuko Kitagawa are the editorial members of the . Annals of Gastroenterological Surgery",

year = "2023",

month = jan,

doi = "10.1002/ags3.12623",

language = "English",

volume = "7",

pages = "7--9",

journal = "Annals of Gastroenterological Surgery",

issn = "2475-0328",

publisher = "Wiley-Blackwell Publishing Ltd",

number = "1",

}

TY - JOUR

T1 - Defining conversion therapy for esophageal squamous cell carcinoma

AU - Matsuda, Satoru

AU - Tsushima, Takahiro

AU - Kato, Ken

AU - Hsu, Chih Hung

AU - Lee, Jang Ming

AU - Wong, Ian Yu Hong

AU - Wang, Hu Lin Christina

AU - Kang, Chang Hyun

AU - Guo, Xufeng

AU - Yamamoto, Shun

AU - Tsuji, Takayuki

AU - Kawakubo, Hirofumi

AU - Takeuchi, Hiroya

AU - Law, Simon

AU - Kitagawa, Yuko

N1 - Funding Information: Conflict of Interest: Yuko Kitagawa reports grants and personal fees from Asahi Kasei Pharma Co., grants, personal fees, and other from Ono Pharmaceutical Co., Ltd., grants and personal fees from Otsuka Pharmaceutical Factory, Inc., grants and personal fees from Nippon Covidien Inc., grants, personal fees, and other from Taiho Pharmaceutical Co., Ltd, grants, personal fees, and other from Chugai Pharmaceutical Co., Ltd., grants, and personal fees from Kaken Pharmaceutical Co., Ltd., personal fees from AstraZeneca K.K., personal fees from Ethicon, Inc., personal fees from Olympus Co., personal fees from Shionogi & Co., Ltd., personal fees and other from Bristol‐Myers Squibb K.K., personal fees from MSD K.K., personal fees from Smith & Nephew KK, personal fees from Aska Pharmaceutical Co., Ltd., personal fees from Miyarisan Pharmaceutical Co. Ltd., personal fees from Toray Industries, Inc., personal fees from Daiichi Sankyo Company, Ltd., personal fees from Chugai Foundation for Innovative Drug Discovery Science, personal fees from Nippon Kayaku Co., Ltd., grants from Yakult Honsha Co. Ltd., grants from Otsuka Pharmaceutical Co., Ltd., grants from Tsumura & Co., grants from Sumitomo Pharma Co., Ltd., grants from EA Pharma Co., Ltd., grants from Eisai Co., Ltd., grants from Kyowa Kirin Co., Ltd., grants from Medicon Inc., grants from Takeda Pharmaceutical Co., Ltd., grants from Teijin Pharma Ltd., outside the submitted work; Ken Kato reports research grants from MSD; Ono Pharmaceutical Co.; Merck Serono; Bayer; Beigene; Oncologys Biopharma; Chugai Pharmaceutical Co.; and Shionogi. Satoru Matsuda, Hiroya Takeuchi, Simon Law, and Yuko Kitagawa are the editorial members of the . Annals of Gastroenterological Surgery

PY - 2023/1

Y1 - 2023/1

KW - conversion surgery

KW - conversion therapy

KW - esophageal squamous cell carcinoma

UR - http://www.scopus.com/inward/record.url?scp=85139992526&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85139992526&partnerID=8YFLogxK

U2 - 10.1002/ags3.12623

DO - 10.1002/ags3.12623

M3 - Editorial

AN - SCOPUS:85139992526

SN - 2475-0328

VL - 7

SP - 7

EP - 9

JO - Annals of Gastroenterological Surgery

JF - Annals of Gastroenterological Surgery

IS - 1

ER -